Cirrus Logic Inc (NASDAQ:CRUS) up marginally, Dendreon Corporation (NASDAQ:DNDN)

Posted by Samantha Donahue May 5, 2013 0 Comment 2116 views


Northern, WI 05/05/2013 (GDPInsider) – Cirrus Logic Inc (NASDAQ:CRUS): There was a rise of 2.16% in Cirrus Logic, Inc (NASDAQ:CRUS) shares in Friday’s trading session. The opening price of the shares was $19.84 which touched an intraday high of $20.22 before dropping slightly to $19.72 percent. Over 3.18M shares were traded in Friday’s trading session which was close to the average volume of 3.19M that was measured over the last 30 days. At the moment, the company has recovered from a 52-week low. This also meant that Cirrus Logic made it to the NASDAQ gainers Watch List.

Cirrus Logic Inc is based in the United States. It supplies digital signal-processing and high-precision analog components that are used in the energy and audio markets. The company products include digital-to-analog converters (DACs), analog-to-digital converters (ADCs) and Codec’s. The latter integrate DACs and ADC’s into a single integrated circuit (IC). These may also be integrated into Class-D digital amplifier-controllers, audio DSPs and power stages. The products that it manufactures are also used in various consumer applications such as tablets, smartphones, portable media players and home theatre systems. Other applications include digital televisions, gaming devices, sound cards and video/audio receivers.

Is CRUS a solid investment at these levels? Get valuable updates and exclusive insights here.

Dendreon Corporation (NASDAQ:DNDN): There was a dip of 0.42% in Dendreon Corporation (NASDAQ:DNDN) shares in Friday’s trading session. The opening price of the shares was $4.80 which touched an intraday high of $4.90 before dropping to $4.61 per share. Over 3.22M shares were traded in Friday’s trading session which was lower than the average volume of 3.73M that was measured over the last 30 days.

Dendreon Corporation is a biotechnology company that is focused on inventing, developing and commercializing therapeutics that could significantly improve the options for treatment of cancer. The product portfolio of the company includes a miniature molecule product candidate and active cellular immunotherapies that could be applied in the treatment of various types of cancer.

Dendreon Corporation (NASDAQ:DNDN)’s first commercialized product to receive U.S Food and Drug Administration approval was PROVENGE. It is an autologus cellular therapy that is used in the treatment of cancers such as minimally symptomatic or asymptomatic, castrate-resistant and metastatic prostate cancer.

How Should Investors Trade DNDN Now? Get the latest trends and data here.

Disclosure:

WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.


About Samantha Donahue

Samantha Donahue is a digital fellow with GDP insider. Samantha earned a Bachelor's degree in Government from Cornell University and later his Master's degree in Journalism from Columbia University. She has also received numerous awards from the Associated Press, Society of Professional Journalists, and other media organizations for many of her exclusive stories. Samantha thrives reporting on breaking news and as a general assignments news reporter.

View all post by Samantha Donahue Visit author's website

Write Your Comment